




PATENT  
Docket No. 280502000200

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on May 28, 2002.

  
Jose Luna

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Chaim M. ROIFMAN, et al.

Serial No.: 09/936,887

Filing Date: September 11, 2001

For: METHODS AND COMPOSITIONS FOR  
TREATING LEUKEMIA

Examiner: To be assigned

Group Art Unit: To be assigned

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This application is a National Phase Application of International Patent Application Number PCT/CA00/00266, filed March 13, 2000, which claims the benefit of Canadian Patent Application Number 2,265,396, filed March 12, 1999.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \* is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of \* is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for


any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 280502000200. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: May 28, 2002

Respectfully submitted,

By: Karen Babyak Dow  
Karen B. Dow  
Registration No. 29,684

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-7960  
Facsimile: (858) 720-5125



Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 2805020002

Application Number 09/936,887

Applicant

Chaim M. ROIFMAN, et al.

Filing Date September 11, 2001

Group Art Unit To be assigned

Mailing Date May 28, 2002

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	06/1993	5,217,999	Levitzki, et al.	514	613	
	2.	06/1998	5,773,476	Gazit, et al.	514	620	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	3.	11/1994	WO 94 26260 A	WIPO			

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	4. ✓	Estrov, et al. "Growth Requirements for Human Acute Lymphoblastic Leukemia Cells: Refinement of a Clonogenic Assay" Cancer Res. 48:5901-5907 (1988)
	5. ✓	Fausser, et al. "Granuloerythropoietic Colonies in Human Bone Marrow, Peripheral Blood, and Cord Blood" Blood 52(6):1243-1248 (1978)
	6. ✓	Fausser, et al. "Culture Studies of Human Pluripotent Hemopoietic Progenitors" Blut 41:327-333 (1980)
	7. ✓	Gazit, et al. "Tyrophostins. 2. Heterocyclic and $\alpha$ -Substituted Benzylidenemalononitrile Tyrophostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases" Journal of Medicinal Chemistry 34(6):1896-1907 (1991)
	8. ✓	Gazit, et al. "Tyrophostins. 3. Structure-Activity Relationship Studies of $\alpha$ -Substituted Benzylidenemalononitrile 5-S-Aryltyrophostins" Journal of Medicinal Chemistry 36:3556-3564(1993)
	9.	Kamel-Reid, et al. "Differential Kinetics of Engraftment and Induction of CD10 on Human Pre-B Leukemia Cell Lines in Immune Deficient <i>scid</i> Mice" Leukemia 6:8-17 (1992)
	10.	Meydan, et al. "Inhibition of Acute Lymphoblastic Leukaemia by a Jak-2 Inhibitor" Nature 379:645-648 (1996)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.